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INTRODUCTION
Hepatitis C virus (HCV) causes persistent chronic 
infection in ≈ 80% of cases, often leading to liver cir-
rhosis and hepatocellular carcinoma. The chronicity 
of HCV infection is mainly a consequence of its con-
siderable genetic heterogeneity (Pawlotsky, 2003). 
Hepatitis C virus has an enveloped single-strand 
positive-sense RNA genome of approximately 9600 
nucleotides in length. Phylogenetic analysis of dif-
ferent HCV genomes has identified six major types 
with about 30% of nucleotide differences (named 1, 
2, 3…) and many different subtypes with about 20% 
of nucleotide differences (named a, b, c…). Like 
other RNA viruses, HCV exists in a single individual 
as a genetically heterogeneous pool of distinct yet 
closely related variants referred to as quasi-species. 
Isolates from one infected person contain many 
different quasi-species with one or two predomi-
nant variants and several minor variants present in 
very low frequencies (Soler et al., 2002; Pawlotsky, 
2003).
It is known that this HCV diversity is reflected 
in the range of responses to interferon (IFN) thera-
py. The genotype is one of the predictive parameters 
currently used to define the antiviral treatment 
strategy and the chance of therapeutic success (Zein, 
2000; Wohnsland et al., 2007). Application of the 
presently most effective combined therapy, pegi-
lated interferon α-2a (PEG-INF)/ribavirin, revealed 
that patients with genotypes 2 and 3 respond more 
promptly, require shorter duration of treatment, and 
have twice the frequency of sustained virological 
response as patients with genotypes 1 and 4 (Zein, 
2000). In addition, numerous results indicate the 
potential impact of viral genetic polymorphism on 
the outcome of antiviral therapy in patients infected 
by the same HCV genotype (Soler et al., 2002).
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Abstract — Different types of interferon are widely used to treat hepatitis C virus (HCV) infection. Results obtained in 
vitro suggest that interferon inhibits internal ribosome entry site (IRES)-mediated translation of the HCV genome. To 
elucidate the possible effect of the nucleotide sequence of IRES on therapy outcome, we compared HCV isolates from 
patients with sustained response and non-response to interferon/ribavirin combination therapy. In 56 analyzed HCV 
isolates, nucleotide changes appeared strictly in the stem-loop IIIb region, the stem part from 243 nt to 248 nt, and the 
polypyrimidine-II region. The natural sequence variability of IRES in isolates of genotype 3a was significantly higher than 
in isolates of genotype 1b (p < 0.05). Тhe average number of nucleotide changes in genotype 3a correlated with response 
to therapy (p < 0.05).
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Variability of the HCV genome is not uniform, 
due to the presence of conservative and hypervari-
able regions. The most conserved parts, the 5’ and 
3’ non-translated regions (NTR), flank the open 
reading frame at each end and contain signals 
required for replication (Zein, 2000; Pawlotsky, 
2003). Moreover, translation of the HCV is regulated 
by the highly conserved region, named the “internal 
ribosome entry site” or IRES, which encompasses 
the 5’ NTR and the first part of the core gene, 
spanning the genome sequence 40-370 nt. The par-
ticular structure of the IRES enables initiation of 
translation in HCV in a cap-independent manner. 
The IRES sequence folds into a complex structure 
grouped in four distinct stem-loop domains: SLI to 
SLIV (Kieft et al., 2001). The HCV IRES is unique 
among the viral IRESs, since it is able to bind to 
the 40S ribosomal subunit without involving most 
canonical translation initiation factors and requires 
only the eIF2-GTP-Met-tRNA complex for interac-
tion (Kieft et al., 2001).
Even though it is the most highly conserved part 
of the virus genome, the 5’ NTR shows quasi-spe-
cies distribution with minor variants in its sequence 
(Buratti et al., 1997; Soler et al.,       2002; van Leeuwen   
et al., 2004). Nucleotide changes in the IRES are sin-
gle nucleotide polymorphisms, including substitu-
tion and insertion/deletion, and occur in the 5’NTR 
in a small percentage of nucleotides and in the core 
gene in about 15% of nucleotides (Pawlotsky, 2003; 
van Leeuwen et al., 2004). In vitro experiments and 
in silico predicted IRES RNA structures suggest that 
some of these small nucleotide changes could have 
dramatic effects on translation efficiency (Buratti 
et al., 1997; van Leeuwen et al., 2004). Additionally,      
these nucleotide changes can influence IRES interac-
tions with some non-canonical trans-acting eukary-
otic cell factors included in the internal initiation of 
HCV RNA translation, like La auto antigen, poly-
pyrimidine (Py) tract binding protein (PTB), and 
poly(rC)-binding protein 2 (Spangberg and Schwart, 
1999; Kieft et al., 2001). 
Some new results indicate that INFs inhibit 
HCV translation not only over double-stranded 
RNA-activated protein kinase and oligoadenylate 
synthetase, but also by suppression of the HCV 
IRES function, even though selective inhibition of 
IRES-mediated translation of viral polyprotein is a 
general mechanism by which IFNs inhibit HCV rep-
lication (Hazari et al., 2005). In view of these data, 
it is proposed that some differences in HCV IRES 
sequences could influence the efficacy of INF thera-
py, but consistent results have not yet been obtained 
(�amamoto et al., 1997; Suzuki et al., 1998; Th�lu et          
al., 2004). In this investigation, we examined nucleo-      
tide changes in the SLII and SLIII part of the IRES 
in relation to PEG-INF/ribavirin therapy response. 
Concerning the influence of other factors on the 
response to therapy, we included in the analyses the 
main clinical characteristics of chronic infection in 
our patients (age, sex, ALT level, stage of fibrosis, 
and HCV RNA level).
MATERIAL AND METHODS
Sixty patients with chronic HCV infection were 
registered randomly in the Clinical Center of Serbia 
and the Military Medical Academy in Belgrade 
between January 2003 and June 2005. All patients 
received PEG-INF (180 µg/week) plus ribavirin 
(800 mg/d) for 24 weeks (HCV genotype 2 and 3) 
or PEG-INF (180 µg/week) plus ribavirin (1000 
mg/d, if their body weight was < 75 kg, or 1200 
mg/d, if it was ≥ 75 kg) for 48 weeks in patients with 
HCV genotypes 1 or 4. Approval from the Ethical 
Review Committee of Clinical Center of Serbia 
was obtained to conduct the study, and written 
informed consent was obtained from all patients. 
Serum RNA-HCV was detected and the concentra-
tion determined with the Amplicor HCV Monitor 
2.0 according to the manufacturer’s instructions 
(Roche Diagnostics, Germany). Histological find-
ings were evaluated according to the stage of fibro-
sis (F0-F3) and cirrhosis 4 by METAVIR score. A 
sustained virological response (SR) was defined as 
the absence of HCV RNA in serum as determined 
by the COBAS Amplicor HCV qualitative test 2.0 
(Roche Diagnostics, Germany) 6 months after the 
end of treatment. Non-response (NR) was defined 
as the presence of serum HCV RNA 6 months after 
the end of treatment.
Isolates of the HCV genome were prepared 
from the patients a month before starting therapy. 
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Ribonucleic acid was extracted from 100 µL of 
serum using a TRIzol kit (BRL Life Technologies, 
Gaithersburg, MD) and dissolved in 25 µL of RNase-
free water. The selected part of the IRES sequence 
was amplified by RT-PCR (QIAGEN One Step 
RT-PCR Kit, Germany) with primers IR-F (ggc-
gacactccaccatagat) and IR-R (cacggtctacgagacctccc), 
which covered 319 nt. We carried out RT-PCR for 
35 cycles (reverse transcription at 50°C for 30 min 
and 95°C for 15 min), followed by amplification at 
94°C for 45 s, 56°C for 45 s, and 72°C for 60 s. In the 
second PCR, the same primers were used as in RT-
PCR, with 0.5 U/reaction Platinum Taq polymerase 
(Invitrogene, Brazil), and the reaction ran for 28 
cycles at 95°C for 3 min, 94°C for 45 s, 58°C for 30 s, 
and 72°C for 60 s (Applied Biosystems Gene Amp® 
PCR System 2700). Before starting the second PCR, 
uracil N-glycosylase (UNG, Fermentas, Lithuania) 
treatment was performed to eliminate carry-over 
contamination. This was done by incubating the 
PCR mix with 15 U of UNG/reaction for 15 min at 
37°C, followed by inhibition of UNG for 5 min at 
95°C. The final PCR products were analyzed electro-
phoretically by polyacrylamide gel electrophoresis 
and visualized with silver nitrate. The total PCR 
product was directly sequenced in both directions 
using the BigDye Terminator v. 3.1 Cycle sequenc-
ing kit with an ABI 3730 DNA automatic sequenc-
er (Applied Biosystems and MWG-Biotech AG, 
Ebersberg, Germany). By this means, we obtained 
the sequence of the most frequent or predominant 
quasi-species in each isolate. In order to screen for 
nucleotide changes in the complete SLII and SLIII 
regions of the IRES, the nucleotide sequence of 
278 nt was analyzed (39 nt to 317 nt, excluding the 
primer regions).
RESULTS AND DISCUSSION
Within the analyzed group, 34 patients were infected 
with genotype 1b (19 patients were SR and 15 
patients were NR) and 22 patients with genotype 
3a (17 patients were SR and five patients were NR). 
Three patients infected with genotype 4 and one 
patient with genotype 2a were excluded from the 
analysis due to the small number for comparison. 
Variability of the IRES nucleotide sequence was 
evaluated in relation to the consensus isolate, which 
was the most frequent in our isolates and in the 
GenBank database (Fig. 1). 
In our analyzed group, 26 (46%) isolates showed 
variations. Thus, 15 isolates exhibited one nucleotide 
change, while nine isolates had two or three nucleo-
tide changes (Fig. 1). Genotype 3a had double the 
average number of nucleotide changes per isolate 
compared with genotype 1b (1.05 ± 1.0 vs. 0.4 ± 0.7, 
P = 0.01). This difference could result from slower 
genetic evolution of HCV genotype 1b, as indicated 
by a significant decrease in its transmission due to 
systematic blood and blood product screening. In 
contrast, the current lack of control of HCV epidem-
ics among intravenous drug users is associated with 
rapid ongoing genetic evolution of HCV genotypes 
1a and 3a, related to their spread (Pawlotsky, 2003; 
Morice et al., 2006).
Nucleotide substitutions in the right-hand part 
of sub-domain IIIb were the most frequent in our 
isolates (19/56). Nucleotide changes G203A and 
C204T in genotype 3a appeared in 14 out of 22 
isolates, and variability in these sites contributed 
considerably to the general genotype 3a variabil-
ity (Fig. 1). The A203 change appeared in 66% of 
sequences and T204 in 16% of sequences of geno-
type 3a in the GenBank database (first 100 BLAST 
hits). In genotype 1b in five isolates, sub-domain 
IIIb showed substitutions C204T and C204A. In the 
GenBank database of genotype 1b, T204 occurred 
in 35% of cases and A204 was very rare (2%, first 
100 BLAST hits). The sub-domain IIIb regulates 
the recruitment of eIF3 and Met-tRNS-eIF2, so the 
substitutions in this sub-domain may have an effect 
on viral translation efficiency (Buratti et al., 1997;    
Kieft et al., 2001).
Considering that initiation of protein transla-
tion may be one factor affecting the level of HCV-
RNA, we compared this clinical characteristic in 
the groups with and without nucleotide changes in 
HCV isolates. In the group with genotype 1b, the 
HCV RNA level was 16.9 ± 31.3 x 105 IU/mL (with-
out nucleotide changes) and 9.4 ± 8.7 x 105 IU/mL 
(with nucleotide changes). In the group with geno-
type 3a, the HCV RNA level was 9.2 ± 12.9 x 105 
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Fig. 1. Alignment of examined IRES HCV sequences from 56 isolates. The sequences are compared to prototype HC-J4 (AF054250) 
for genotype 1b and NZL1 (D17763) for genotype 3a (www.ncbi.nlm.nih.gov/Genbank). The short lines indicate identity with the 
prototype HCV sequences. Dots indicate larger regions without any nucleotide changes (130-200 nt and 210-240 nt). The abbrevia-
tion SR stands for sustained responder, NR for non-responder. Numbers below SR or NR indicate overall numbers of detected iso-
lates with the given sequence. The shown nucleotide sequences are deposited in the GenBank database (www.ncbi.nlm.nih.gov/Gen-
bank) under accession numbers for genotype 1b: EU164929, EU164966, and EU164931 to EU 164964; for genotype 3a: EU164930, 
EU164965, and EF193864 to EF193883.
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IU/mL (without nucleotide changes) and 7.0 ± 9.2 x 
105 IU/mL (with nucleotide changes). Although we 
found large differences in the mean level of HCV-
RNA between the two groups of patients, statistical 
significance was absent. Similarly, there were great 
differences in the HCV RNA level in relation to 
therapy response, but without statistical significance 
(Table 1). The very high variances within tested 
groups indicate that these analyses should be done 
in a larger group of patients.
We found that some parts of the IRES were 
conservative, suggesting great importance of these 
structures in its function. First of all, the entire SLII 
of the IRES sequence was monomorphic, which 
agrees with earlier results for prevalent quasi-spe-
cies variants (�amamoto et al., 1997; Suzuki et al.,       
1998). Also, we detected some absolutely conserva-
tive regions in the SLIII domain, which are contact 
points with eIF3 (160-167 nt), one of the major PTB 
protein-binding sites (Py-III region from 191-199 
nt), and the four-way junction (SLIIIabc) structure. 
These are simultaneously involved in the recruit-
ment of eIF3 and the 40S ribosomal subunit (Kieft 
et al., 2001). In addition, our findings showed that 
IRES contact points with the 40S ribosomal sub-
unit were unaltered (128-138 nt, 145-156 nt, and 
237-250 nt). Finally, these regions were conserved 
across all the standard genotypes of HCV (Buratti 
et al., 1997; Hazari et al., 2005).     In silico results 
showed that the rare nucleotide changes which we 
detected in this region (G243A, CT247/8TC) did 
not have a particular effect on stem-loop III fold-
ing (Moratorio et al., 2007). Moreover, all other 
nucleotide changes detected in our isolates were 
located in single-stranded parts of the IRES (Py-II, 
sub-domain IIIb, and unpaired nucleotide G243). 
These results are consistent with other investigations 
concerning sequence variability of IRES, suggesting 
that maintaining the predicted secondary structures 
of IRES is an important prerequisite for survival 
advantage of the prevalent quasi-species in host cells 
(Suzuki et al., 1998; Th�lu et al., 2004).   
As in other investigated populations, some nucle-
otide changes in the IRES were exclusively observed 
in NR or SR patients (Magrin et al., 1996; �amamoto 
et al., 1997; Suzuki et al., 1998; �asmeen et al., 2003;         
Th�lu et al., 2004; Moratorio et al., 2007). For exam-      
ple, we detected a single nucleotide polymorphism 
in the Py-II region in isolates of genotype 3a from 
NR patients (Fig. 1). Also, the transition TC247/8CT 
was found in genotype 1b and SR patients, while in 
other populations it occurred in solitary cases with 
a different response to therapy (Magrin et al., 1996; 
�amamoto et al., 1997; Suzuki et al., 1998; Th�lu      
et al., 2004). It is clear that the prevalence of these        
substitutions is too small to indicate any correlation 
with response to interferon therapy.
Table 1. Clinical characteristics of patients and nucleotide variation of IRES in relation to therapy response. Categorical data were 
compared by the χ2 and Fisher’s exact probability test. a) Data expressed as mean ± SD; b) Stage of fibrosis expressed by METAVIR 
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Age (years) a 45.39±9.80 45.88±13.72 45.62±11.62 ns 34.71±10.32 43.6±8.14 36.73±10.41 ns 0.005
Sex (male/female) 12/7 8/7 - ns 13/4 5/0 - ns ns
ALT level a 84.6±34.8 101.2±47.4 92.4±41.4 ns 89.1±55.7 109.0±42.6 93.6±52.8 ns ns
Stage of fibrosis a, b 2.4±1.4 2.4±1.6 2.4±1.5 ns 1.5±1.0 3.0±1.0 1.9±1.2 0.011 ns
HCV RNA level a, c 5.3±2.8 23.9±34.9 14.2±25.5 ns 8.1±10.1 9.9±13.4 8.5±10.5 ns ns
Number of NC 0.6±0.9 0.3±0.6 0.4±0.7 ns 0.8±0.7 1.8±1.3 1.0±1.0 0.040 0.010
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On the other hand, with regard to the aver-
age number of nucleotide changes between patient 
groups SR and NR, a significant difference appeared 
for genotype 3a (Table 1). In vitro results in the cell 
culture model suggest that selective inhibition of 
IRES-mediated translation of viral polyprotein is 
a general mechanism by which INF inhibits HCV 
replication. However, the mode of this inhibition 
and the influence of particular IRES primary and 
secondary structures is unknown so far (Buratti et  
al., 1997; Kieft et al., 2001; Kato et al., 2002; Hazari 
et al., 2005). Beyond that, some new results have 
shown different HCV quasi-species distribution 
during INF therapy (Th�lu et al., 2007; Zekri et al.,   
2007). Thus, we can conclude that more nucleotide        
changes in NR than in SR patients found in geno-
type 3a could be important for the mechanism of 
INF action, but comparison of the prevalent quasi-
species before and after therapy would be necessary 
in this kind of investigation.
Besides viral features, many factors regard-
ing biochemical and histological characteristics of 
chronic HCV infection can influence the effects 
of antiviral therapy (Craxì et al., 1996; Magrin et 
al., 1996; Zein, 2000; Pawlotsky, 2003). When we 
divided the patients into SR and NR groups, no 
significant differences in the tested clinical param-
eters were obtained, except for stage of fibrosis in 
the group with genotype 3a (Table 1). However, in 
this type of investigation, we should consider that 
the clinical characteristics of HCV infection in 
some instances depend on the duration of infection. 
Since, the precise duration of HCV infection in most 
patients is not assessed, some authors use age as a 
surrogate for disease duration (Craxì et al., 1996; 
Magrin et al., 1996). In our population, the patients 
with genotype 1b were significantly older than those 
with genotype 3a (p < 0.01). This finding confirms 
previous results for patients from Serbia and other 
European countries, which indicates changes in the 
prevalence of HCV types according to age (Svirtlih 
et al., 2007). In addition, SR and NR patients with 
HCV 3a isolates differed in average age by approxi-
mately 10 years, but the range of ages was wide, 
from 17 to 55 years. These results suggest that the 
influence of viral determinants on INF action would 
be clearer in a more homogenous population of 
patients in relation to the main features of chronic 
inflammatory processes important for therapy suc-
cess (Craxì et al., 1996; Magrin et al., 1996; Buratti et  
al., 1997; Wohnsland et al.,   2007). This examination 
is in progress. 
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Ин­терферон­ска терапија се дан­ас н­ајчешће кори-
сти у лечењу ин­фекције вирусом хепатитиса типа C 
(HCV). Ин витро резултати су показали да ин­тер-
ферон­ ин­хибира тран­слацију код овог вируса преко 
ин­теракције са делом ген­ома који учествује у ин­ици-
јацији тран­слације тзв. „ун­утрашње рибозомалн­о 
улазн­о место“ (IRES). У овом раду смо испитивали 
н­уклеотидн­е измен­е у IRES-у код изолата HCV-а 
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добијен­их из серума особа које су примале комбин­о-
ван­у терапију ин­терферон­/рибавирин­. У ан­ализира-
н­ој групи од 56 HCV изолата, н­уклеотидн­е измен­е 
су утврђен­е у: IIIб петљи, регији између 243 н­т и 
248 н­т и полипиримидин­-II регији. Утврђен­а варија-
билн­ост IRES-а код изолата ген­отипа 3а зн­ачајн­о је 
већа у поређењу са изолатима ген­отипа 1б (p < 0.05). 
Просечан­ број н­уклеотидн­их измен­а код изолата 
ген­отипа 3а је у корелацији са одговором н­а приме-
њен­у терапију (p < 0.05).
